Stock OVID OVID THERAPEUTICS INC.
Add to a list
To use this feature you must be a member
Log inSign up

Insiders Ovid Therapeutics Inc.

Equities

OVID

US6904691010

Market Closed - Nasdaq
Other stock markets
 21:00:00 10/05/2024 BST 		5-day change 1st Jan Change
3 USD -1.64% Intraday chart for Ovid Therapeutics Inc. -1.96% -6.83%
04-30 B. Riley Securities Initiates Ovid Therapeutics With Buy Rating, $9 Price Target MT
04-29 HC Wainwright Starts Ovid Therapeutics With Buy Rating, $9 Price Target MT

Insiders

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Ovid Therapeutics Inc. Announces Changes to Its Board
CI
Ovid Therapeutics Expands Epilepsy Development Expertise with New Appointments
CI
Ovid Therapeutics Appoints Dr. Kevin Fitzgerald to Board of Directors
CI
Ovid Therapeutics Inc. Appoints Robert Michael Poole as Member of Audit Committee and Compensation Committee of the Board
CI
Ovid Therapeutics Inc. Announces Executive and Board Appointments
CI
Ovid Therapeutics Inc. Strengthens Board & Leadership Team to Focus Efforts on Expanding Its Neurosciences Capabilities
CI
Ovid Therapeutics Inc. Appoints Jeff Rona as Chief Financial Officer
CI
Ovid Therapeutics Inc. Announces Management Changes
CI
Ovid Therapeutics Inc. Appoints Joy A. Cavagnaro and Dr. Bruce A. Sullenger to Scientific Advisory Board
CI
Ovid Therapeutics Inc. Announces Resignation of Douglas Williams from Board and All Committees
CI
Ovid Therapeutics Announces Appointment of Robert S. Langer as Chair of its Scientific Advisory Board
CI
Ovid Therapeutics Inc. Names Alexander Kolevzon, M.D., to Scientific Advisory Board
CI
Ovid Therapeutics Appoints Jason Tardio as Chief Commercial Officer
CI
Ovid Therapeutics Inc. Announces Management Changes
CI
Ovid Therapeutics Inc. Announces Executive Changes
CI
Ovid Therapeutics Inc. Announces Executive Changes
CI
Dr. Yaron Werber, Chief Business and Financial Officer to Leave Ovid Therapeutics Inc., Effective September 21, 2018
CI
Ovid Therapeutics Appoints Ana C. Ward as Senior Vice President and General Counsel
CI
Ovid Therapeutics Inc. Appoints Barbara G. Duncan as Director
CI
Ovid Therapeutics Names Jacqueline A. French to Scientific Advisory Board
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. OVID Stock
  4. News Ovid Therapeutics Inc.
  5. Insiders